Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CCXI $5.20 0.7800 +17.65%
STML $7.81 1.0200 +15.02%
OMED $14.62 1.0400 +7.66%
ARGS $5.96 0.4000 +7.19%
TGTX $7.73 0.5100 +7.06%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

VRML $1.21 -0.0900 -6.92%
GTXI $0.72 -0.0300 -4.00%
TKMR $4.10 -0.1600 -3.76%
MACK $6.31 -0.2300 -3.52%
IMDZ $12.56 -0.3800 -2.94%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 877 | 878 | 879 | 880 | 881 | 882 | 883 | 884 | 885 | 886 | Next > | Last >>

Medicare Overpaid $15 Million for Roche Cancer Drug, OIG Says

(Bloomberg) Feb 1, 2013 - Medicare, the U.S. health insurance program for the elderly and disabled, overpaid for Roche Holding AG’s Herceptin breast-cancer treatment by about $15 million, according to a government investigation.
read article 

Roche’s Avastin Fails to Win NICE Backing for Ovarian Use

(BloombergBusinessweek) Jan 31, 2013 - Roche Holding AG’s anti-tumor drug Avastin failed for the second time in two months to win the backing of the U.K.’s health-cost regulator as a treatment for ovarian cancer in a draft decision issued today.
read article 

The Clash of the Six-Figure Drugs

(Wall Street Journal/Corporate Intelligence blog) Jan 31, 2013 - It’s rare that a rare disease gets a new treatment, let alone two.
read article (paid subscription required) 

AstraZeneca, Bristol-Myers’s Forxiga Not Backed by NICE

(Bloomberg) Jan 31, 2013 - AstraZeneca Plc and Bristol-Myers Squibb Co.’s drug Forxiga failed to win the backing of the U.K.’s health-cost adviser when used with other diabetes treatments after the companies didn’t offer a discount.
read article 

AstraZeneca, Bristol-Myers Deepen Diabetes Alliance

(Wall Street Journal) Jan 31, 2013 - AstraZeneca and Bristol-Myers Squibb Co. have deepened their diabetes-drug partnership by merging their diabetes marketing teams and moving them to a new U.S. headquarters separate from either company, AstraZeneca's new chief executive, Pascal Soriot, said in an interview.
read article (paid subscription required) 

Report Faults High Fees for Out-of-Network Care

(New York Times) Jan 31, 2013 - A health insurance industry report contrasts some of the highest bills charged by non-network providers in 30 states with Medicare rates for the same services.
read article 

Though Obamacare Pays Less, Providers Flock To 'Bundled' Medicare Payments

(Forbes) Feb 1, 2013 - In yet another blow to traditional fee-for-service medicine where doctors and hospitals are paid for each service provided for each patient’s illness or course of treatment, the Obama administration says more than 500 hospitals and related health care organizations have agreed to be paid “bundled payments” as part of a three-year initiative.
read article 

A Doctor’s Struggle With Numbers

(New York Times/Well blog) Jan 31, 2013 - Oncologists are notoriously bad at predicting survival. We try to provide hope, but not false hope.
read article 

Dr. Marcus Neubauer Joins McKesson Specialty Health as Medical Director, Oncology Services

(The US Oncology Network) Jan 25, 2013 - McKesson Specialty Health and The US Oncology Network today announced that Marcus Neubauer, M.D., has accepted the position of medical director, Oncology Services for McKesson Specialty Health, effective March 1.
read corporate press release 

The LIVESTRONG Foundation Offering $1.2 Million in Funding to 72 Sites Across the Nation to Improve the Lives of People Affected by Cancer

( Jan 31, 2013 - The LIVESTRONG Foundation is offering $1.2 million in implementation awards to 72 sites across the nation as part of its 2013 Community Impact Project.
read press release 

New Institute for Precision Medicine Created at Weill Cornell Medical College and NewYork-Presbyterian Hospital

(Weill Cornell) Jan 31, 2013 - Dr. Mark Rubin, leading prostate cancer and genomics expert, to lead cutting-edge center for targeted, individualized patient care based on each patient's genetics.
read press release 

New NCCN Guidelines for Patients® Available for Adolescents and Young Adults with Cancer

(NCCN) Jan 28, 2013 - NCCN announces the availability of NCCN Guidelines for Patients®: Caring for Adolescents and Young Adults, a patient-friendly translation of the NCCN Guidelines® focused on people diagnosed with cancer between the ages of 15 and 39.
read press release 

ASCO and National Cancer Policy Forum Host Workshop on Cancer Clinical Trials System

(ASCO in Action) Jan 27, 2013 - ASCO and the Institute of Medicine’s National Cancer Policy Forum will co-host a workshop on Implementing a National Cancer Clinical Trials System for the 21st Century, Feb. 11-12, 2013.
read article 

ASCO and FDA Host Workshops on Minimal Residual Disease

(ASCO in Action) Jan 30, 2013 - ASCO and the Food and Drug Administration are hosting two workshops, Feb. 27 and March 4, that will provide a forum for discussion of extending the qualification of minimal residual disease (MRD) detection as a prognostic biomarker to that of an efficacy/response biomarker in evaluating new drugs for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
read article 

Sequestration: The Cliff for Oncology?

(COA) Feb 1, 2013 - At the 12th hour last year, Congress came up with a deal to patch the SGR for a year. With that, they also patched sequestration for two months.
read article 

ASCO Presses Administration on Sequestration

(ASCO in Action) Feb 1, 2013 - ASCO and the American College of Cardiology (ACC) sent a letter to President Barack Obama, urging him to prevent a triple-threat of devastating budget cuts threatened by sequestration.
read article 

Teva Ends Collaboration on CureTech’s Cancer Medicine

(Bloomberg) Jan 31, 2013 - Teva Pharmaceutical Industries Ltd. ended an alliance with an Israeli biotechnology company for the development of an experimental cancer drug as Chief Executive Officer Jeremy Levin narrows the company’s research focus.
read article 

Cerulean Announces First Patient Dosed in Randomized Phase 2 Study of CRLX101 in Advanced Small Cell Lung Cancer

(Fort Mill Times) Jan 31, 2013 - Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase 2 study of its lead candidate, CRLX101, in patients with extensive-stage small cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy.
read article 

How Cancer Cells Rewire Their Metabolism to Survive

(Sanford-Burnham/Beaker blog) Jan 31, 2013 - Researchers discover that tumors lacking the protein PKCζ are good at surviving when nutrients are scarce—opening a new therapeutic avenue that targets cancer metabolism.
read article 

Blood Vessel Cells Coax Colorectal Cancer Cells into More Dangerous State

(MD Anderson) Jan 31, 2013 - Blood vessels that supply oxygen and nutrients to tumors can also deliver something else - a signal that strengthens nearby cancer cells, making them more resistant to chemotherapy, more likely to spread to other organs and more lethal, scientists at The University of Texas MD Anderson Cancer Center report online in Cancer Cell.
read press release 

IU Researcher's Lung Cancer Work May Someday Improve Standard of Care

(Simon Cancer Center) Jan 23, 2013 - Lung cancer researchers at Indiana University Melvin and Bren Simon Cancer Center are developing new anti-cancer agents that may someday improve the current standard of care.
read press release 

IU Physician Researcher Testing Novel Surgical Technique for Uterine, Cervical Cancer Patients

(Simon Cancer Center) Jan 24, 2013 - A technique initially used to spare breast tissue during surgery is being researched by an Indiana University School of Medicine physician to improve prognosis, reduce complications and spare lymph nodes in women with gynecological cancer.
read press release 

Two-Step Immunotherapy Attacks Advanced Ovarian Cancer, Penn Medicine Researchers Report

(Penn Medicine) Jan 31, 2013 - Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies. In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania School of Medicine show that a two-step personalized immunotherapy treatment — a dendritic cell vaccine using patients’ own tumor followed by adoptive T cell therapy — triggers anti-tumor immune responses in these type of patients.
read press release 

Europe Says Drug Makers Paid to Delay a Generic

(New York Times) Jan 31, 2013 - European antitrust officials on Thursday accused the drug giants Johnson & Johnson and Novartis of colluding to delay the availability of a less expensive generic version of a powerful medication often used to ease severe pain in cancer patients.
read article 

Gilead Seeks Blood Cancer Drugs to Bolster HIV Business

(Bloomberg) Feb 1, 2013 - Gilead Sciences Inc., the world’s largest maker of HIV drugs, has spent $1.2 billion in two years to buy blood cancer drugs. It’s looking for more.
read article